Related Experiment Video
Updated: Jun 22, 2025
Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing
Published on: September 25, 2011
Prognostic and therapeutic insights into colorectal carcinoma through immunogenic cell death gene profiling
Jinglu Yu1, Yabin Gong2, Zhenye Xu3
1PuDong Traditional Chinese Medicine Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China, Shanghai, Pudong, China.
Abstract:
While the significance of immunogenic cell death (ICD) in oncology is acknowledged, its specific impact on colorectal carcinoma remains underexplored. In this study, we delved into the role of ICD in colorectal carcinoma, a topic not yet comprehensively explored. A novel ICD quantification system was developed to forecast patient outcomes and the effectiveness of immunotherapy. Utilizing single-cell sequencing, we constructed an ICD score within the tumor immune microenvironment (TIME) and examined immunogenic cell death related genes (ICDRGs). Using data from TCGA and GEO, we discovered two separate molecular subcategories within 1,184 patients diagnosed with colon adenocarcinoma/rectum adenocarcinoma (COADREAD). The ICD score was established by principal component analysis (PCA), which classified patients into groups with low and high ICD scores. Further validation in three independent cohorts confirmed the model's accuracy in predicting immunotherapy success. Patients with higher ICD scores exhibited a "hot" immune phenotype and showed increased responsiveness to immunotherapy. Key genes in the model, such as AKAP12, CALB2, CYR61, and MEIS2, were found to enhance COADREAD cell proliferation, invasion, and PD-L1 expression. These insights offered a new avenue for anti-tumor strategies by targeting ICD, marking advances in colorectal carcinoma treatment.
Insights
This study introduces a new immunogenic cell death (ICD) score to predict colorectal cancer patient outcomes and immunotherapy response. Higher ICD scores indicate a better response to cancer treatments.
Area of Science:
- Oncology
- Immunology
- Genomics
Background:
- Immunogenic cell death (ICD) is crucial in oncology, but its role in colorectal carcinoma is not fully understood.
- Understanding ICD's impact can improve treatment strategies for colorectal cancer.
Purpose of the Study:
- To investigate the role of ICD in colorectal carcinoma.
- To develop a novel ICD quantification system for predicting patient outcomes and immunotherapy effectiveness.
- To identify molecular subtypes within colorectal cancer based on ICD characteristics.
Main Methods:
- Utilized single-cell sequencing to create an ICD score within the tumor immune microenvironment (TIME).
- Analyzed immunogenic cell death-related genes (ICDRGs) in 1,184 colorectal adenocarcinoma patients from TCGA and GEO datasets.
- Employed Principal Component Analysis (PCA) for ICD score establishment and validated the model in three independent cohorts.
Main Results:
- Identified two distinct molecular subtypes in colorectal adenocarcinoma based on ICD scores.
- The developed ICD score accurately predicted immunotherapy success.
- Patients with high ICD scores demonstrated a 'hot' immune phenotype and better immunotherapy response.
- Key genes (AKAP12, CALB2, CYR61, MEIS2) were linked to increased tumor proliferation, invasion, and PD-L1 expression.
Conclusions:
- The novel ICD score serves as a reliable predictor of patient prognosis and immunotherapy response in colorectal carcinoma.
- Targeting ICD presents a promising strategy for advancing anti-tumor therapies in colorectal cancer.
- The findings contribute to a deeper understanding of the tumor immune microenvironment in colorectal cancer.
